Information Provided By:
Fly News Breaks for May 30, 2017
NBIX
May 30, 2017 | 08:44 EDT
Jefferies analyst Biren Amin said his firm's survey of 25 payors found that the majority of payors plan to restrict Neurocrine's Ingrezza to moderate-severe tardive dyskinesia patients. Despite this feedback, consensus estimates for 2017 and 2018 appear achievable, Amin tells investors in a research note. He keeps a Buy rating on Neurocrine with a $66 price target.
News For NBIX From the Last 2 Days
NBIX
NBIX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.